Masseter Botox: Jaw Slimming Timeline, Results and Risks

A function-and-contour timeline at a glance

This timeline separates muscle activity, chewing function and visible contour. A smaller-looking lower face is a later muscle-volume question—not an injection-day result and not proof that every broad jaw is caused by the masseter.

The bars organize assessment priority only. They are not muscle-thickness measurements, dose recommendations, treatment ratings or jaw-width forecasts.

Why relaxing one muscle does not reshape every jaw layer

Botulinum toxin reduces acetylcholine signaling at the treated neuromuscular junction. In the masseter, activity can fall before repeated use and muscle bulk decline enough to change the lower-face contour. That sequence differs from an injection that adds or removes volume.

The visible jaw outline also reflects mandibular bone, superficial and deep fat, parotid tissue, skin, retaining structures and other muscles. A broad or asymmetric lower face therefore does not diagnose masseter hypertrophy, and reducing the masseter cannot promise a V-line, lift loose skin or treat a dental cause.

Function belongs in the result assessment. Clenching strength, chewing comfort, smile excursion and symmetry should be documented alongside 3D or photographic contour because a cosmetically smaller measurement is not a complete outcome if function changes unexpectedly.

How to interpret the stages

A recovery timeline combines broad observations from published patient guidance. It cannot know the exact product or device, treatment depth, technique, medical history, skin characteristics or aftercare plan involved in one person’s case.

Use the stages to understand the order in which changes may happen and to prepare questions for a qualified professional. Do not use a general internet timeline to override instructions from the clinician who assessed and treated you.

Function, documentation and safety principles

• Record the exact product, total and per-side treatment record, muscles treated, date and planned review; potency units cannot be converted between botulinum toxin products.
• Use neutral, clenching and smiling views with the same lens, distance, head position and lighting. A relaxed front photograph alone cannot show muscle function.
• Ask whether the goal is cosmetic contour, pain, bruxism or another condition. Evidence and authorization for one purpose do not automatically transfer to another.
• Do not use an online face-width ratio, sex, ethnicity or desired V-shape to calculate units. Anatomy, asymmetry, chewing function and the product-specific label require qualified assessment.
• Before treatment abroad, verify the product and practitioner locally and obtain an after-hours contact plus a record that another clinician can understand.

Why the same jaw-width concern may need a different assessment

Questions before treating a chewing muscle for contour

• Is the lower-face prominence actually caused by the masseter, and how will that be assessed during clenching?
• Is the purpose cosmetic contour, bruxism, pain or another diagnosis, and what evidence applies to that exact purpose?
• What product is proposed, is this use authorized locally and why can its units not be compared with another toxin?
• How will neutral, clenching, smiling, chewing function and asymmetry be recorded before and after treatment?
• Who provides urgent and routine follow-up if smile, chewing, swallowing, speech or breathing changes?

Sources

1. FDA: BOTOX Cosmetic Prescribing Information

   October 2024 U.S. indications, non-interchangeable potency units and boxed warning. Masseter prominence or jaw slimming is not listed as a U.S. cosmetic indication in this label.

2. JAAD: Randomized Phase 2 OnabotulinumtoxinA Study

   Twelve-month multicenter study measuring masseter prominence and 3D lower-face volume at day 90; a localized smile effect occurred in four participants in the highest-dose arm. Industry affiliations are disclosed in the paper.

3. Scientific Reports: Randomized Triple-Blind Masseter Trial

   Muscle thickness, electrical activity and chewing performance through six months after one or repeated abobotulinumtoxinA treatment; repeated treatment produced functional changes.

4. Dermatologic Surgery: PrabotulinumtoxinA Phase 3 Trial

   Placebo-controlled study using muscle thickness and 3D imaging; the largest mean differences were reported at 12 weeks. Product and population cannot be generalized to every toxin.

5. Journal of Cosmetic Dermatology: Review of Masseter Injection Adverse Events

   Review of 36 reports describing complication types, timing and recovery; many appeared within two to four weeks and resolved within 12 weeks.

6. UK MHRA: Updated Botulinum Toxin Safety Warning

   July 2026 safety update on authorized products, qualified practitioners and urgent swallowing, speech or breathing symptoms after therapeutic or cosmetic use.